Allison Crowell, MD
Neurology · Lancaster, PANPI 1114312568
Payments from drug & device makers
Across 144 payments — averaging $123.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$10K
- AstraZeneca$4K
- UCB, Inc.$515
- EMD Serono, Inc.$349
- AbbVie$343
- E.r. Squibb & Sons, L.L.C.$292
- plus $2K from 17 others
What the payments were for
- Consulting fees$2,62515%
- Speaking & faculty fees$9,40053%
- Travel & lodging$3172%
- Food & beverage$5,43631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 25 | $10,376 |
| AstraZeneca | 15 | $3,626 |
| UCB, Inc. | 5 | $515 |
| EMD Serono, Inc. | 10 | $349 |
| AbbVie | 28 | $343 |
| E.r. Squibb & Sons, L.L.C. | 4 | $292 |
| Neurocrine Biosciences, Inc. | 3 | $258 |
| Amneal Pharmaceuticals LLC | 10 | $249 |
| Biogen | 9 | $234 |
| Impel Pharmaceuticals Inc. | 2 | $181 |
| Bristol Myers Squibb | 4 | $178 |
| Lundbeck LLC | 3 | $176 |
| Novartis | 8 | $165 |
| TG Therapeutics, Inc. | 2 | $152 |
| Harmony Biosciences LLC | 4 | $131 |
| Boston Scientific | 1 | $123 |
| Medtronic | 1 | $113 |
| Alnylam Pharmaceuticals Inc. | 2 | $99 |
| SK Life Science, Inc. | 2 | $66 |
| Pfizer | 3 | $61 |
| Merz Pharmaceuticals, LLC | 1 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,778 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 12 | $674,265 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $316,927 |
| Emgality PenGalcanezumab-Gnlm | 68 | $52,547 |
| Nurtec OdtRimegepant Sulfate | 31 | $34,421 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 33 | $28,857 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $24,941 |
| BotoxOnabotulinumtoxina | 18 | $22,656 |
| EliquisApixaban | 20 | $17,186 |
| Mycophenolate Mofetil | 56 | $11,630 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 13 | $10,453 |
| NayzilamMidazolam | 14 | $10,038 |
| RytaryCarbidopa/Levodopa | 19 | $8,203 |
| Pyridostigmine Bromide | 107 | $8,158 |
| Levetiracetam | 133 | $5,506 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 139 | $4,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris | $3,626 | $674,26512 claims |
| PfizerNurtec Odt, Eliquis | $61 | $51,60751 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Rytary, Pyridostigmine Bromide | $249 | $27,991182 claims |
| AbbVieBotox | $343 | $22,65618 claims |
| UCB, Inc.Nayzilam | $515 | $10,03814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Lancaster
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.